Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): Protocol for a randomized clinical trial by G.L. Botto et al.
STUDY PROTOCOL Open Access
Treatment of atrial fibrillation with a dual
defibrillator in heart failure patients (TRADE HF):
protocol for a randomized clinical trial
Giovanni Luca Botto1*, Giuseppe Boriani2, Stefano Favale3, Maurizio Landolina4, Giulio Molon5, Claudio Tondo6,
Mauro Biffi7, Giuseppe Grandinetti8, Paolo De Filippo9, Giovanni Raciti10, Luigi Padeletti11
Abstract
Background: Heart failure(HF) and atrial fibrillation(AF) frequently coexist in the same patient and are associated
with increased mortality and frequent hospitalizations. As the concomitance of AF and HF is often associated with
a poor prognosis, the prompt treatment of AF in HF patients may significantly improve outcome.
Methods/design: Recent implantable cardiac resynchronization (CRT) devices allow electrical therapies to treat AF
automatically. TRADE-HF (trial registration: NCT00345592; http://www.clinicaltrials.gov) is a prospective, randomized,
double arm study aimed at demonstrating the efficacy of an automatic, device-based therapy for treatment of
atrial tachycardia and fibrillation(AT/AF) in patients indicated for CRT. The study compares automatic electrical
therapy to a traditional more usual treatment of AT/AF: the goal is to demonstrate a reduction in a combined
endpoint of unplanned hospitalizations for cardiac reasons, death from cardiovascular causes or permanent AF
when using automatic atrial therapy as compared to the traditional approach involving hospitalization for
symptoms and in-hospital treatment of AT/AF.
Discussion: CRT pacemaker with the additional ability to convert AF as well as ventricular arrhythmias may play a
simultaneous role in rhythm control and HF treatment. The value of the systematic implantation of CRT ICDs with
the capacity to deliver atrial therapy in HF patients at risk of AF has not yet been explored. The TRADE-HF study
will assess in CRT patients whether a strategy based on automatic management of atrial arrhythmias might be a
valuable option to reduce the number of hospital admission and to reduce the progression the arrhythmia to a
permanent form.
Trial registration: NCT00345592
Background
Heart failure (HF) and atrial fibrillation (AF) are two of the
major diseases affecting older adults and, when chronic,
are often associated with increased mortality, frequent
hospitalizations and decreased quality of life [1-3]. These
two disorders share similar characteristics and frequently
coexist in the same patient, with the prevalence of AF
increasing together with the severity of HF [4-7]. The
association of AF with a worse prognosis in HF patients is
still under debate with controversial results in favor [2,5,8]
or against [9,10]. Even though data regarding improved
survival rates is currently lacking, as far as health care is
concerned, one goal of AF treatment in HF patients is to
reduce hospitalization and improve quality of life [11].
The recent introduction of an implantable device which
can provide both cardiac resynchronization therapy (CRT)
and ventricular and atrial electrical therapies, paves the
way toward the combined treatment of both diseases. In
fact, CRT has proven to be effective in correcting asyn-
chrony in HF [12-14], while defibrillation therapy has
demonstrated its effectiveness in treating both ventricular
and atrial arrhythmias [15-17]. Due to the high prevalence
of AF in HF patients who meet indications for an implan-
table cardioverter defibrillator (ICD) [18,19], this com-
bined therapy could treat HF, prevent sudden cardiac
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death, prevent AF and restore sinus rhythm when neces-
sary. As AF may compromise the efficacy of CRT in terms
of reverse remodeling [20,21] a break in the AF/HF cycle
could improve prognosis both by optimizing HF treatment
and restoring sinus rhythm. The TRADE-HF study has
been designed to assess the benefits of an automatic,
device-based management of atrial arrhythmias in patients
suffering from symptomatic HF, indicated for CRT treat-
ment with defibrillation backup and implanted with a dual
(atrial and ventricular) defibrillator.
Methods/Design
Study Design and Objectives
The TRADE-HF is a prospective, open-label, rando-
mized, multi-center, two parallel arm study. The study
has been approved by the local Ethic Committees of all
20 participating centers and has been registered to
http://www.clinicaltrials.gov site (NCT00345592). Enroll-
ment started in November 2006. The steering commit-
tee of the study is responsible for the study design and
its amendments.
Primary objective of the TRADE-HF study is to demon-
strate a reduction in the combination of hospitalizations
for cardiovascular causes or death for cardiovascular
causes or development of permanent AF, using a device-
based treatment of atrial arrhythmias (i.e. automatic
therapy) compared to a traditional approach including
hospitalization for symptoms and and/or in-hospital treat-
ment of AT/AF (i.e. traditional therapy). Automatic ther-
apy implies that atrial arrhythmias are detected by the
device itself which treats the rhythm automatically within
3 hours after episode onset with a predetermined sequence
of programmed electrical therapies (anti-tachycardia
pacing and electrical shock). On the other side in the tra-
ditional arm automatic shock therapy is not active; there-
fore, patients who will experience symptomatic atrial
arrhythmias at home will refer to their center, where treat-
ment of the atrial arrhythmia will be done according to
center’s practice (e.g. drugs, external cardioversion, device
shock commanded by the physician in a hospital environ-
ment). Hospitalizations for cardiovascular causes will
include any unplanned cardiac cause hospitalization
including day hospital, access to the emergency units and
in-hospital procedures of AT/AF cardioversion. Perma-
nent AF is considered as any form of AF that is found to
be refractory to drug or electrical therapy, for which the
physician resigns to take additional actions to restore
sinus rhythm and that persists additionally for at least one
month. After obtaining informed consent, a three-month
observation period ensues, during which the device para-
meters are optimized, data on atrial arrhythmias are col-
lected and patient’s response to the device treatment is
assessed. Thereafter, patients are randomized to the two
different treatment arms, automatic and traditional
therapy in a 1:1 ratio. After being randomized, patients are
followed for three years to assess endpoints. The study
flowchart is shown in figure 1.
Secondary objectives include: the performance assess-
ment of automatic atrial therapies, and a comparison
between the automatic-managed and traditional therapy
arm of the following outcomes: in-hospital costs, Quality
of Life (QoL) scores, number of hospital admissions and
the separate components of the primary endpoint.
An exploratory analysis will be done in order to investi-
gate the response to CRT treatment for the enrolled
patients. A positive response to CRT is considered a rela-
tive LVEF increase ≥ 20% and/or a relative LVESV
decrease ≤ 15% measured at echocardiographic recording
associated with a functional assessment defined as reduc-
tion of at least one NYHA class or of 15 points at Minne-
sota living with heart failure score for NYHA class III
patients or at least stable NYHA class or 10 points
decrease at Minnesota living with heart failure score for
NYHA class II patients. This definition reflects patient’s
cardiac remodeling associated to a functional improve-
ment in highly symptomatic patients or at least a stable
functional condition in mild symptomatic patients. The
proportion of CRT responders will be analyzed at time of
randomization and one year after randomization; addi-
tionally a correlation, separately at the two time points,
will be searched among the proportion of CRT respon-
ders, the burden of atrial fibrillation (total percentage of
recorded AT/AF episodes: 0; <10%; >10%) and the target
site of left ventricular lead (lateral wall vs. other).
Patient Selection
Patients who meet all of the following criteria are consid-
ered eligible to take part in the study: 1) chronic (>6 weeks)
Figure 1 Study flowchart. RND: Randomization.
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symptomatic HF despite stable, optimal drug therapy for
HF and AF, 2) patients scheduled for and implanted with a
cardiac resynchronization device with defibrillator backup
according to current guidelines. 3) age 18 or above, or of
legal age to give informed consent according to specific
national regulations. Principal exclusion criteria include:
1) chronic or persistent atrial fibrillation refractory to medi-
cal or electrical therapy 2) valve disease, and/or patients
with or who are likely to receive a mechanical tricuspid
valve during the course of the study 3) patients who have
undergone (or are scheduled to undergo) an intervention of
atrial fibrillation ablation 4) cerebral vascular event or tran-
sient ischemic attack within 12 months of implantation
which lead to significant impairment 5) life expectancy of
less than 1 year due to other medical conditions 6) NYHA
class IV. According to the listed criteria, patients are not
selected on the basis of atrial arrhythmia recurrence, except
for chronic/persistent AF.
Interventions and Follow Up
After obtaining informed consent, patients’ baseline data
are collected, including demographic background and
medical history. A clinical evaluation performed at the
time of enrollment includes NYHA class assessment, an
electrocardiogram, an echocardiogram and Qol assess-
ment using the Minnesota-Living With Heart Failure
questionnaire. During the three-month observation per-
iod before randomization, we collect data on the inci-
dence of supraventricular arrhythmia and clinical events;
deaths from any cause or chronic atrial fibrillation before
randomization are considered dropouts. Patients are ran-
domized by means of a centralized, computer-generated
randomization list, with a 1:1 ratio; given that both
patients and physicians are aware of the randomized
treatment and that patients are specifically trained to
manage their symptoms in two different ways depending
on the study arm, patients and investigators are not
blinded with respect to treatment. At the randomization
visit, NYHA class, QoL and atrial and ventricular func-
tion are assessed (the latter by echocardiography) in
order to evaluate the response to CRT. After randomiza-
tion, patients are followed up for a total duration of
3 years, with planned ambulatory visits every 6 months.
At follow-up visits a clinical assessment is performed
including NYHA class staging, ECG and medical ther-
apy. QoL assessment and echocardiography are manda-
tory one and two years after randomization. Data
regarding events such as hospitalization are collected
over the entire follow-up period.
Device shocks and all interventions performed to treat
atrial arrhythmias (drug, electrical or other therapy,
repeated or not) are collected for both study arms. A pro-
tocol for the management of atrial arrhythmias in the tra-
ditional arm has not been predefined, but left to center’s
specific therapeutic practice and decision making, and
may range from simple observation of the response to
drugs of the hospitalized patient to repeated attempts of
internal cardioversion done with the device in a in-
hospital environment. The only requirements for this
arm are 1) automatic shock set to “off” and 2) arrhythmia
treatment performed at in-hospital environment.
If a primary endpoint event, other than patient death,
occurs, the patient continues to be followed over the
entire 2-year period in order to assess secondary
endpoints. Crossover may occur at any point during the
follow-up: patients may withdraw from the device-
controlled therapy arm when atrial shock therapy is dis-
abled due to severe discomfort related to shocks or too
frequent atrial shock therapies; patients may cross from
the traditional therapy to the device-controlled arm
when atrial shock therapy is enabled chiefly because the
number of hospital admissions for atrial cardioversion
becomes too frequent. Patients who present with perma-
nent/chronic AF, regardless of the randomization arm,
start rate control therapy with the device’s atrial therapy
set to off: this is not considered a crossover, as the
patient has already reached the primary endpoint.
Sample Size
Patients treated for CRT in two large randomized clini-
cal trials, the COMPANION [13] and CARE-HF [14]
studies, yielded a respective incidence of 62% and 38%
in deaths or hospitalizations due to cardiac reasons after
a two-year follow-up period. According to the AFFIRM
study [22], the evolution to chronic AF may range
between 20% and 25% after two years, in patients who
are likely to experience recurrent AT/AF. In HF
patients, the prevalence of AF is reported to vary from
10% to 50%, with higher values in older patients and in
those with superior NYHA class [23]. Additionally, the
incidence of new-onset AF in these patients ranges from
3% and 10% per year [23]. A study of a large cohort of
heart failure patients has recently revealed that around
one third of hospitalized patients had ECG evidence of
AF [24]. Based on these data, we assumed that around
35% of patients in both study arms of the TRADE-HF
study will have experienced at least one episode of atrial
arrhythmia after three years and that around 60% will
have experienced at least one hospitalization for cardiac
reasons or persistent/chronic AF or death from cardio-
vascular causes. Patients treated automatically with the
device are expected to have a lower rate of events. The
effectiveness of treating AT/AF with a dual-defibrillator
is very high and reported to be around 90% in different
settings [15,16]. Assuming a 60% risk for combined end-
points in the traditional arm versus a 43% risk in the
device-managed arm, using a two-tailed alpha of 0.05,
with a Cox proportional hazards regression model the
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study will need a total of 360 patients (180 per group) in
order to achieve a power of 90% and demonstrate a dif-
ference in primary endpoint rates among patients in the
device-managed arm versus those in the traditional arm.
Assuming a 15% attrition rate during the study, due to
loss to follow-up or failure to adhere to the study
design, the total sample size will amount to 414 patients
(207 per group).
Data Analysis
Descriptive statistics will be presented for the collected
variables, overall and according to the randomization
group; for categorical variables absolute and relative fre-
quencies; for continuous variables mean, standard devia-
tion, median, 25th-75th percentile, minimum and
maximum. Baseline characteristics of the two study
arms will be listed. Cox modeling will be used to per-
form the primary analysis and assess the association
between treatment (traditional vs. device-managed) and
the primary endpoint. Hazard ratios and their 95% con-
fidence intervals will be presented together with Kaplan-
Meier cumulative survival and with event rates (per 100
persons per year) in each group. The model will include
the following potential confounders: evidence of AT/AF
in the patient’s medical history or recorded by the
device before randomization and patients’ response to
CRT at randomization. In particular, group effects will
be tested by interaction terms comparing the treatment
effect in patients who are or are not responders to CRT
at randomization. Competing events (causes of death
other than cardiovascular, transplant or ventricular assist
device implant) will be censored at the time they occur.
The primary analysis will be done according to Inten-
tion to treat (ITT) i.e. automatic shocks programmed
according to randomization. Survival analysis techniques
will be used to evaluate time-to-event for the evolution
to chronic AF and for both subgroup analyses (CRT
responders and AT/AF). In case the primary endpoint is
fulfilled, additional post-hoc analyses will be performed.
In particular a positive response to CRT responsiveness
will be analyzed with respect to the planned variables by
means of a logistic regression model. The device’s ability
to manage and correctly classify atrial arrhythmia will
be evaluated considering the sensitivity, specificity and
accuracy of the device’s classification compared to that
made by the Event Committee. Quality of life scores,
number and total duration of hospital admissions (for
all causes, cardiac causes and for heart failure), total
duration of AF and total costs will be compared
between the two study arms after 3 years using the
appropriate statistical test, according to distribution. For
economic analysis costs are estimated for hospitalization
(reasons, entry date, duration, department), interven-
tions and instrumental examinations performed.
A P value of at least 0.05 will be used for statistical
significance.
Data Safety and Monitoring Plan
Prior to initiating the study at each site, the Sponsor
shall visit the site to ensure understanding of the proto-
col and that the involved staff has sufficient time and
facilities to conduct the study. During the course of the
study additional visits may be conducted at regular
intervals, to assess the continued compliance with the
study protocol and applicable regulations, that data are
collected in a timely accurate and complete manner and
that study records are adequately maintained at the site.
Necessity and frequency of site visits are determined on
basis of the data quality and completeness, as periodi-
cally retrieved with the interrogation of the online data-
base of the study. All Study Events, including Adverse
Events (whether serious or not), patient withdrawals,
deviations and therapies to treat AF, are reported to the
Sponsor via electronic e-mail notification and processed
within one working day. Adverse Events are analyzed,
and reported to competent authorities when needed.
Investigators are responsible for providing the Sponsor
with a description of each reported adverse event
including the suspected cause, what corrective actions
were taken and what the clinical outcome was for the
patient. All events relevant for primary endpoint analy-
sis, including recorded episodes of atrial arrhythmias
will be adjudicated by a board of independent physicians
(Event Committee) blinded with respect to device classi-
fication and to the randomization arm.
Discussion
Both heart failure and atrial fibrillation affect several
million patients in the United States and cause substan-
tial morbidity and mortality [1-3] representing a serious
issue in terms of health care. The link between the two
pathologies is well-documented: the presence of HF has
been identified as one of the most powerful independent
predictors of AF, with a 6-fold increase in the relative
risk of its development [4], while the prevalence of AF
increases together with the severity of HF and ranges
from 5% in NYHA classes I-II to 45% in NYHA class IV
[5,6], with a higher incidence of new onset AF in
patients with more severe HF [7]. Additionally, the two
diseases share common risk factors such as hyperten-
sion, diabetes, coronary artery disease and valve disease
[2]. As far as prognosis is concerned, AF as a co-
morbidity affects both morbidity and mortality: patients
affected by both diseases have an increased risk of hos-
pitalization and embolic events, with AF being a non-
independent predictor of mortality [5]. This association
between HF and the development of AF has been
emphasized as a two-fold vicious cycle, and the issue as
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to whether an effective treatment of one of the two con-
ditions may have an effect on the other has recently
become a subject of interest [11,25]. AF treatment and
sinus rhythm maintenance, (i.e. rhythm control) is con-
sidered to have several advantages in HF patients such
as improved hemodynamic, restoration of contractile
function and the possible regression of tachycardiomyo-
pathies. Analyses conducted on the AFFIRM and DIA-
MOND data revealed favorable outcomes of rhythm
control in HF subsets [26,27]. Nevertheless, data from a
large prospective randomized study, the AF-CHF trial
[28,29] enrolling patients with a left ventricular ejection
fraction of 35% or less, symptoms of congestive heart
failure, and a history of atrial fibrillation, assessed that a
routine strategy of rhythm control does not reduce the
rate of death from cardiovascular causes, as compared
with a rate-control strategy. On the other hand, patients
with cardiac dyssynchrony and reduced ejection fraction,
currently meet class I indications for CRT. Additionally,
recent guidelines have introduced this option also for
patients with persistent AF and indications for AV junc-
tion ablation (class IIa, level of evidence C) [30]. As only
few patients enrolled in the AF-CHF trial were meeting
indications for ICD or CRT (only 7% had an implantable
device according to current international practice) the
concomitant treatment of HF and AF through resyn-
chronization and automatic cardioversion in this patient
may lead to a different picture. A particular care should
be deserved for those HF patients with low burden of
AF or who did not show clinical episodes of AF at the
time of device implant, and that may develop AF over
time, that are reported to reach up to 20%-25% of
patients in a mid-term timeframe [20,31]. Indeed some
studies showed that new onset AF after CRT implanta-
tion is associated with a poor response to CRT, [20,21]
and that a positive response to CRT, on the other side,
is associated with a decreased AF burden [32]: those
subjects may therefore benefit from the concomitant
treatment of HF through resynchronization and AF
though rhythm control.
In this panorama, developments in implantable devices
pave the way toward the treatment of the two concomi-
tant diseases by a single device: a CRT pacemaker with
the additional ability to convert AF as well as ventricular
arrhythmias may play a simultaneous role in rhythm
control and HF treatment. The safety and performance
of internal atrial cardioversion has been already tested
in ICD recipients without heart failure. Internal atrial
cardioversion has been shown to be an effective treat-
ment for atrial arrhythmias ensuring the successful con-
version of most AF episodes, often requiring only a
single shock or atrial anti-tachycardia pacing (ATP) and
leading to a decrease in the frequency of long-lasting
episodes [16-18]. However, the benefits of dual chamber
ICDs equipped with atrial therapies go beyond the effi-
cacy of atrial shocks as this therapy could be able to:
relieve patients’ symptoms, limit adverse events such as
stroke, thromboembolism, recurrent hospitalizations,
improve hemodynamic function and prevent ventricular
tachycardia or fibrillation triggered by atrial tachyar-
rhythmias [17,33]. As regards heart failure, the value of
the systematic implantation of CRT ICDs with the capa-
city to deliver atrial therapy in HF patients with a his-
tory (or at risk) of AF, has not yet been explored and
some authors have suggested that this aspect be exam-
ined in prospective studies [11,34,35]. Implantable CRT
devices that include low energy atrial cardioversion as
well as electrical therapy for ventricular arrhythmias,
have recently made it possible to explore this field. The
TRADE-HF study is designed to assess whether a strat-
egy by means of automatic management of atrial
arrhythmias might be a valuable option to reduce the
number of cardiovascular cause hospital admission,
death for cardiovascular causes and the progression the
arrhythmia to a persistent form. After receiving thor-
ough training on enrollment, it is assumed that patients
without the automatic atrial shock will refer to a hospi-
tal if severe or persisting symptoms occur, which could
lead to AF diagnosis and cardioversion if required.
Therefore, AF will be adequately treated in both arms,
albeit diagnosis, timing and methods of treating the
arrhythmia will vary. Although we do not know whether
these different methods for delivering atrial therapy may
have a different impact specifically on quality of life and
the number of hospital admissions for heart failure, the
automatic therapy arm would appear to have several
advantages. Automatic atrial shocks, when therapy is
successful and in the absence of recurrences, success-
fully manages electrical cardioversion without the need
for hospital treatment, thus reducing the number of
hospital admissions. Automatic therapy may shorten the
time between AF onset and sinus rhythm restoration
when compared to the in-hospital approach. One possi-
ble (positive) side effect of this timely approach is a
reduced occurrence of successive atrial arrhythmias as
well as possible fewer hospitalizations for heart failure
due to the detrimental effect of AF. Finally, automatic
therapy can treat asymptomatic episodes promptly: with
a traditional approach based on symptoms and in-hospi-
tal cardioversion, these episodes may not be detected
until they degenerate into symptomatic HF. In general,
the automatic treatment of AF may be an option for a
prompt treatment strategy, while a more traditional
approach, based on in-hospital cardioversion, may delay
effective treatment, and possibly worsen heart failure.
Despite this study is not powered to explore this poten-
tial specific clinical benefit, any differences observed in
the component of the primary endpoints or in
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secondary endpoints (i.e permanent AF or cardiac cause
hospitalizations) could be useful to generate further
hypotheses on this topic.
Early treatment of AF also seems to be justified as far
as histopathology is concerned, as arrhythmia is not
only an electrical pathology, but a condition that, over
an extended time, may induce non-reversible organic
diseases such as fibrosis and conduction abnormalities
[34-37]. In light of this, early AF treatment could be
reserved even for those patients with a lower AF burden
or for those with no history of AF. A recent work by
Saxon et al. reports that 25% of CRT candidates with a
history of AF, experience recurrent AF within 6 months
of implant [38]. Given the high prevalence of AF in
patients currently indicated to CRT, and the opportunity
to treat new onset AF promptly, the inclusion criteria of
the TRADE HF study consider all patients implanted
with a biventricular device with defibrillator, regardless
of their atrial arrhythmic history.
Finally, whether CRT may have an effect on AF bur-
den in patients with persistent or paroxysmal AF is still
a matter of research and prospective studies to evaluate
this impact have been encouraged [33]. It is not known
whether reverse remodeling, induced by biventricular
pacing in patients who respond to CRT, may have an
effect on the incidence of AT/AF: minimal data exist on
the effect of long term CRT on left atrial dimensions
and/or LV reverse remodelling in patients with AF and
the results are contradictory [8,31,39] even if a recent.
The TRADE HF study will analyze if there are substan-
tial differences in the incidence and characteristics of
atrial fibrillation between CRT responders and
non-responders.
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